Improved outcomes with minimally invasive pancreaticoduodenectomy in patients with dilated pancreatic ducts: a prospective study

• Published in: Surgical endoscopy Vol. 36; no. 5; pp. 3100 - 3109
• Main Authors: Cos, Heidy, LeCompte, Michael T., Srinivasa, Sanket, Zarate Rodriguez, Jorge, Woolsey, Cheryl A., Williams, Gregory, Patel, Siddarth, Khan, Adeel, Fields, Ryan C., Majella Doyle, Maria B., Chapman, William C., Strasberg, Steven M., Hawkins, William G., Hammill, Chet W., Sanford, Dominic E.
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.05.2022; Springer Nature B.V
• Subjects: Abdominal Surgery; Anemia; Blood transfusions; Endoscopy; Fistula; Gastroenterology; Gynecology; Hepatology; Hospitals; Humans; Laparoscopy; Laparoscopy - adverse effects; Length of stay; Medicine; Medicine & Public Health; Mortality; Pancreatic Ducts - surgery; Pancreatic Neoplasms - surgery; Pancreaticoduodenectomy; Pancreaticoduodenectomy - adverse effects; Patients; Postoperative Complications - epidemiology; Postoperative Complications - etiology; Postoperative Complications - surgery; Proctology; Prospective Studies; Retrospective Studies; Robotics; Surgery; Minimally invasive pancreatoduodenectomy; Laparoscopic; Robotic; Outcomes; Ideal outcome
• ISSN: 0930-2794; 1432-2218
• DOI: 10.1007/s00464-021-08611-x

Background Little is known about what factors predict better outcomes for patients who undergo minimally invasive pancreaticoduodenectomy (MIPD) versus open pancreaticoduodenectomy (OPD). We hypothesized that patients with dilated pancreatic ducts have improved postoperative outcomes with MIPD compared to OPD. Methods All patients undergoing pancreaticoduodenectomy were prospectively followed over a time period of 47 months, and perioperative and pathologic covariates and outcomes were compared. Ideal outcome after PD was defined as follows: (1) no complications, (2) postoperative length of stay < 7 days, and (3) negative (R0) margins on pathology. Patients with dilated pancreatic ducts (≥ 3 mm) who underwent MIPD were 1:3 propensity score-matched to patients with dilated ducts who underwent OPD and outcomes compared. Likewise, patients with non-dilated pancreatic ducts (< 3 mm) who underwent MIPD were 1:3 propensity score-matched to patients with non-dilated ducts who underwent OPD and outcomes were compared. Results 371 patients underwent PD—74 (19.9%) MIPD and 297 (80.1%) underwent OPD. Overall, patients who underwent MIPD had significantly less intraoperative blood loss. After 1:3 propensity score matching, patients with dilated pancreatic ducts who underwent MIPD ( n  = 45) had significantly lower overall complication and 90-day readmission rates compared to matched OPD patients ( n  = 135) with dilated ducts. Patients with dilated duct who underwent MIPD were more likely to have an ideal outcome than patients with OPD (29 vs 15%, p  = 0.035). There were no significant differences in postoperative outcomes among propensity score-matched patients with non-dilated pancreatic ducts who underwent MIPD ( n  = 29) compared to matched patients undergoing OPD ( n  = 87) with non-dilated ducts. Conclusions MIPD is safe with comparable perioperative outcomes to OPD. Patients with pancreatic ducts ≥ 3 mm appear to derive the most benefit from MIPD in terms of fewer complications, lower readmission rates, and higher likelihood of ideal outcome.